Scancell Holdings plc (SCNLF)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 19.86 Million GBP | 1.7% |
| 2023 | 19.53 Million GBP | 138.82% |
| 2022 | 8.17 Million GBP | -47.08% |
| 2021 | 15.45 Million GBP | 11880.62% |
| 2020 | 129 Thousand GBP | 0.0% |
| 2019 | - GBP | 0.0% |
| 2018 | - GBP | 0.0% |
| 2017 | - GBP | 0.0% |
| 2016 | - GBP | 0.0% |
| 2015 | - GBP | 0.0% |
| 2014 | - GBP | 0.0% |
| 2013 | - GBP | 0.0% |
| 2012 | - GBP | 0.0% |
| 2011 | - GBP | 0.0% |
| 2010 | - GBP | 0.0% |
| 2009 | - GBP | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 19.81 Million GBP | 1.57% |
| 2024 Q4 | 19.86 Million GBP | 0.0% |
| 2024 Q1 | 19.5 Million GBP | -0.12% |
| 2023 Q4 | 19.53 Million GBP | 1.59% |
| 2023 FY | 19.53 Million GBP | 138.82% |
| 2023 Q3 | 19.22 Million GBP | 102.99% |
| 2023 Q1 | 9.15 Million GBP | 11.91% |
| 2023 Q2 | 9.47 Million GBP | 3.49% |
| 2022 Q3 | 18.71 Million GBP | 134.91% |
| 2022 FY | 8.17 Million GBP | -47.08% |
| 2022 Q2 | 7.96 Million GBP | 5.99% |
| 2022 Q1 | 7.51 Million GBP | -51.37% |
| 2022 Q4 | 8.17 Million GBP | -56.29% |
| 2021 Q4 | 15.45 Million GBP | 1.36% |
| 2021 FY | 15.45 Million GBP | 11880.62% |
| 2021 Q3 | 15.24 Million GBP | 332.54% |
| 2021 Q2 | 3.52 Million GBP | 1.44% |
| 2021 Q1 | 3.47 Million GBP | 2593.8% |
| 2020 Q4 | 129 Thousand GBP | 63.29% |
| 2020 Q1 | - GBP | 0.0% |
| 2020 FY | 129 Thousand GBP | 0.0% |
| 2020 Q2 | - GBP | 0.0% |
| 2020 Q3 | 79 Thousand GBP | 0.0% |
| 2019 Q3 | - GBP | 0.0% |
| 2019 Q4 | - GBP | 0.0% |
| 2019 Q1 | - GBP | 0.0% |
| 2019 Q2 | - GBP | 0.0% |
| 2019 FY | - GBP | 0.0% |
| 2018 Q2 | - GBP | 0.0% |
| 2018 Q1 | - GBP | 0.0% |
| 2018 FY | - GBP | 0.0% |
| 2018 Q4 | - GBP | 0.0% |
| 2018 Q3 | - GBP | 0.0% |
| 2017 Q1 | - GBP | 0.0% |
| 2017 Q4 | - GBP | 0.0% |
| 2017 Q2 | - GBP | 0.0% |
| 2017 FY | - GBP | 0.0% |
| 2017 Q3 | - GBP | 0.0% |
| 2016 Q1 | - GBP | 0.0% |
| 2016 FY | - GBP | 0.0% |
| 2016 Q4 | - GBP | 0.0% |
| 2016 Q3 | - GBP | 0.0% |
| 2016 Q2 | - GBP | 0.0% |
| 2015 Q4 | - GBP | 0.0% |
| 2015 FY | - GBP | 0.0% |
| 2015 Q3 | - GBP | 0.0% |
| 2015 Q2 | - GBP | 0.0% |
| 2015 Q1 | - GBP | 0.0% |
| 2014 Q3 | - GBP | 0.0% |
| 2014 Q2 | - GBP | 0.0% |
| 2014 Q1 | - GBP | 0.0% |
| 2014 FY | - GBP | 0.0% |
| 2014 Q4 | - GBP | 0.0% |
| 2013 Q4 | - GBP | 0.0% |
| 2013 FY | - GBP | 0.0% |
| 2013 Q2 | - GBP | 0.0% |
| 2013 Q3 | - GBP | 0.0% |
| 2012 Q2 | - GBP | 0.0% |
| 2012 FY | - GBP | 0.0% |
| 2012 Q4 | - GBP | 0.0% |
| 2011 Q4 | - GBP | 0.0% |
| 2011 FY | - GBP | 0.0% |
| 2011 Q2 | - GBP | 0.0% |
| 2010 FY | - GBP | 0.0% |
| 2009 FY | - GBP | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 51.785% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -381.956% |
| SQZ Biotechnologies Company | 27.47 Million USD | 27.684% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 54.197% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 33.262% |
| Mesoblast Limited | 118.7 Million USD | 83.264% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -1994.971% |
| Genus plc | 233.1 Million USD | 91.477% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -577.931% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1378.583% |
| Marizyme, Inc. | 18.71 Million USD | -6.136% |
| ContraFect Corporation | 2.88 Million USD | -589.552% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -2548.8% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -14562.661% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -1273.556% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -754.101% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -251.092% |
| MultiCell Technologies, Inc. | 202.58 USD | -9806396.199% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 65.444% |
| EV Biologics, Inc. | 1.49 Million USD | -1229.051% |
| Q BioMed Inc. | 4.1 Million USD | -383.36% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 39.984% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -3052.948% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -1517.277% |
| Biomind Labs Inc. | 735.54 Thousand USD | -2600.865% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 88.419% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -52.851% |
| Skye Bioscience, Inc. | 4.61 Million USD | -330.441% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -2137.001% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -13937.79% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -238.37% |
| IMV Inc. | 28.88 Million USD | 31.221% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -77142.506% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -779.657% |
| GB Sciences, Inc. | 1.75 Million USD | -1029.195% |
| Alpha Cognition Inc. | 1.22 Million USD | -1527.864% |
| HST Global, Inc. | 98.31 Thousand USD | -20105.657% |
| CSL Limited | 12.18 Billion USD | 99.837% |
| Halberd Corporation | 150 Thousand USD | -13144.0% |
| Enzolytics Inc. | 996.33 Thousand USD | -1893.902% |
| Resverlogix Corp. | 6.49 Million USD | -206.055% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -4060.419% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -7672.544% |
| argenx SE | 20 Million USD | 0.67% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 56.396% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -633.414% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -194188.509% |
| Genscript Biotech Corporation | 417.73 Million USD | 95.244% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -9802.5% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -728.536% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -8564.099% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 70.631% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -556.469% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -5422.782% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 2.273% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -13263.919% |
| BioStem Technologies, Inc. | 4.71 Million USD | -321.657% |
| ONE Bio Corp. | 19.71 Million USD | -0.766% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -7840.619% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -7887.295% |
| Agentix Corp. | 50 Thousand USD | -39632.0% |
| LadRx Corporation | 33.6 Thousand USD | -59014.444% |
| Cell Source, Inc. | 9.25 Million USD | -114.671% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -2527.069% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -2527.069% |
| NovAccess Global Inc. | 2.19 Million USD | -803.049% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -180.878% |
| Itoco Inc. | 228.37 Thousand USD | -8598.774% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -9316.282% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -298.675% |
| Kadimastem Ltd | 891.22 Thousand USD | -2129.064% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -4843.648% |
| CytoDyn Inc. | 30.07 Million USD | 33.947% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -4002.138% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -5546.204% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -154.042% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -16117.143% |
| Rebus Holdings, Inc. | 310 Thousand USD | -6308.387% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -319.532% |
| International Stem Cell Corporation | 4.17 Million USD | -375.491% |
| Bioxytran, Inc. | 1.92 Million USD | -932.0% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -31729.907% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -810.908% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -138.889% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -131.404% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -1177.163% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -7312.687% |
| Neutra Corp. | 54.15 Thousand USD | -36582.916% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -985.574% |
| PureTech Health plc | 25.51 Million USD | 22.131% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -1522.74% |
| IXICO plc | 472.02 Thousand USD | -4108.693% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -28.159% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 68.093% |
| CSL Limited | 12.18 Billion USD | 99.837% |
| Cellectis S.A. | 92.77 Million USD | 78.587% |